Aligos Therapeutics Q3 2024 GAAP EPS $(3.07) Misses $(2.15) Estimate, Sales $1.269M Beat $333.333K Estimate
Aligos Therapeutics Q3 2024 GAAP EPS $(3.07) Misses $(2.15) Estimate, Sales $1.269M Beat $333.333K Estimate
aligos therapeutics 2024年第三季度GAAP每股收益爲$(3.07)，低於$(2.15)的預估，銷售額爲126.9萬美元，超過33.3333萬美元的預估
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(3.07) per share which missed the analyst consensus estimate of $(2.15) by 42.79 percent. The company reported quarterly sales of $1.269 million which beat the analyst consensus estimate of $333.333 thousand by 280.70 percent. This is a 41.09 percent decrease over sales of $2.154 million the same period last year.
aligos therapeutics（納斯達克：ALGS）報告每股虧損$（3.07），比分析師共識估計的$（2.15）低了42.79%。公司季度銷售額爲$126.9萬，高出分析師共識估計的$33.3333萬，增長幅度爲280.70%。這較去年同期的$215.4萬銷售額下降了41.09%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間